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to the study of adverse reactions only (13
October, p 940). Properly, epidemiological
pharmacology is the study of human popula-
tions exposed to pharmacological agents.
However, it is only one of the tools used in
social pharmacology. This wideranging
discipline, analogous to social medicine, is
concerned with the effects on society of ex-
posure to drugs, the reasons for that exposure,
and the social factors influencing the use of
drugs.' These factors include the economic
and political ones affecting prescribing practice.
I therefore support Professor Lawson's
plea that more pharmacoepidemiologists
should be encouraged and hope that they
would come from a wide range of disciplines.
TIMOTHY JERRAM
High Royds Hospital,
Ilkley LS29 6AQ
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Who needs clinical pharmacology?
SIR,-It is open season on clinical pharma-
cology in the medical weeklies. Hard on the
heels of an Italian group accusing clinical
pharmacology of having lost its way' comes a
distinguished British professor of medicine
asking who needs clinical pharmacology
(27 October, p 1119).
At least our Italian colleagues did us the
courtesy of presenting some data, on which
they based their conclusions. Professor J R A
Mitchell chooses instead his review of a
textbook of clinical pharmacology (of which
incidentally he did not disapprove) to vent his
spleen on a discipline with which I had
always assumed he enjoyed cordial relations.
His attack is not only on clinical pharma-
cology. He apparently does not believe that
pharmacology should ever have been separated
from biochemistry and physiology. This is an
argument which I had thought was settled
some 30 years ago. Rereading some of Pro-
fessor Mitchell's own substantial scientific
contributions, one would have perhaps expected
a slightly more gracious attitude towards the
achievements of pharmacology, since he has
relied on them quite heavily. He further
denigrates pharmacology by placing it in an
inferior position to therapeutics, which he
finds difficulty in separating from medicine.
It is sad that he does not appreciate the
continuity of the discipline of pharmacology,
stretching from the study of the fundamental
properties of a drug (including its chemistry
and mode of action) to investigation of the
drug in volunteers and patients before its
introduction into medicine. There is no
justification for choosing any one part of this
process as being more important than another:
the chemist provides the tools for the pharma-
cologist to investigate and the doctor to use.
He uses the example of the time course of
the hypotensive effect of atenolol to belittle
human pharmacology. Any clinical pharma-
cologist worth his salt would have told him
that neither the kinetics of a 3 blocker nor its
dynamics as measured by inhibition of
isoprenaline induced tachycardia gives any
guidance to the duration of hypotensive
activity of agents in this group.
Academic and industrial clinical pharma-
cology are robust enough to withstand this
baseless type of attack, but the part of the
discipline working within the National Health
Service is more fragile. Professor Mitchell is
indeed fortunate to work in an environment
where his colleagues in gastroenterology,
oncology, cardiology, and endocrinology are
so well informed in clinical pharmacology
matters; in this he must be virtually unique.
The encouragement of effective, safe, and
economical prescribing (which are the aims of
clinical pharmacology) within the National
Health Service deserves more encouragement
from Professor Mitchell than he seems pre-
pared to give.
Professors of medicine might be better
advised to tend to the not inconsiderable
problems in their own discipline2 3 and put
their own houses in order before interfering
in matters which they clearly do not under-
stand.
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SIR,-Professor J R A Mitchell uses a book
review to criticise the relevance of basic
medical sciences (including pharmacology)
and of clinical pharmacology to clinical
medicine. He shares the opinion of Macfarlane
Burnet that "Almost none of modern basic
research in the medical sciences has any
direct or indirect bearing on the prevention
of disease or on the improvement of medical
care." Although the strength of an argument
is not measured by Nobel laureates, I believe
that the major contributions of Yalow,
Schally, Samuelson, and Vane cast doubt on
that view. This year's Nobel prize award to
Cesar Milstein and Georges Kohler for their
work on monoclonal antibody production is
another example of the relevance of basic
medical research to the progress of clinical
medicine.
Professor Mitchell sees the clinician as a
car driver and the scientist as an engineer or
designer. He forgets that medical students (for
which Girdwood's book was written, after all)
may wish to become scientists instead of, or
as well as, clinicians. Even the full time
clinician will benefit from a knowledge of
science, as the driver does from some under-
standing of engineering and design.
His second doubt concerns the existence of
clinical pharmacology as a separate discipline.
He contends that it attempts to fuse two
disparate parts (pharmacology and thera-
peutics), which should have been kept separate.
As someone concerned in both activities, I
believe that it is precisely the failure of some
physicians to recognise the natural unity of
the two that has led to the necessity for the
growth of clinical pharmacology. My own
experience has convinced me that clinical
pharmacologists can have fruitful collaboration
with colleagues in the "organ based"
specialties, and I certainly do not feel un-
wanted or unneeded.
Professor Mitchell tells us that the main
problems in medicine are whether to use
drugs rather than what the drugs are or even
how to use them. To return to his own chosen
analogy: if he believes that the decision about
whether to drive a car can be made without
reference to the ability to recognise the
appropriate vehicle and handle it. properly, I
hope I am well away from the public highway
when he sallies forth on his next excursion
into unfamiliar territory.
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SIR,-I had a profound sense of deja vu when
reading Professor J R A Mitchell's review.
Surely we do not have to reopen the issue of
whether clinical pharmacology is a discrete
discipline: its permanent posts, its own
journals, its national and international meet-
ings, its role in district general hospitals' all
attest to the fact that it is established. What is
more alarming is the curious assertion that
medical science can be neatly slotted into
named files-pharmacology into one, for
example, and therapeutics into another, and
never should the twain meet. This view
ignores the essential issue that drugs are
chemicals and that when a doctor administers a
chemical to a patient looking for its effect his
or her observations will be incomplete if he
ignores the fact that the chemical must be
absorbed, distributed round the body, and
eliminated from it. It is not necessary to
carry in the mind the rate constants for
transfer of drug from one mathematical body
compartment to another, but some knowledge
of a drug's kinetics may help to explain why
treatment fails-for example, because of
enzyme induction-or gives adverse results-
for example, because of impaired renal
function. Awareness of these problems has
come not from therapeutists but from clinical
pharmacologists. I agree that the average car
driver need not understand the structural
formula of petrol, but it may help to know
when the fan belt is slack. To regard it as
sufficient knowledge about a drug to "see if it
works" is to aspire to a knowledge that is less
than complete. Who needs clinical pharma-
cology? Professor Mitchell, perhaps you do.
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Maggots dyed with chrysoidine
SIR,-We must concur with Mr G M Sole
(20 October, p 1043) about the strong
circumstantial evidence for the possible
carcinogenic properties of chrysoidine. Not
only has this been shown to be carcinogenic in
mice, as stated; it is also a potent mutagenic
agent in bacteria.'
Transitional cell carcinoma is rare in the
younger patient. We are currently treating
only two young men, both anglers, with this
diagnosis. One man of 35 presented eight
years ago and has multiple invasive tumours
and dysplasia of the whole urothelium,
recently necessitating a nephroureterectomy.
He is a non-smoker who has worked all his
life in computer programming but, when
fishing, used bronze maggots for at least five
years. The second man, aged 26, has undergone
cystoscopy twice, which has shown a single
well differentiated tumour and area of
dysplasia on each occasion. He is a smoker
but again has had no industrial exposure to
